Amneal Pharmaceuticals, Inc.
AMRX
Peringkat dalam Saham
#2968
Amneal Pharmaceuticals, Inc., operating alongside its various subsidiaries, is... Amneal Pharmaceuticals, Inc., operating alongside its various subsidiaries, is a diversified pharmaceutical company involved in the development, acquisition of licenses, manufacturing, marketing, and distribution of both generic and specialized medicinal products. These offerings span a multitude of delivery formats and target a wide range of therapeutic needs. Its operations are structured into three distinct divisions: Generics, Specialty, and AvKARE. The Generics division is responsible for creating, producing, and bringing to market a diverse portfolio of complex pharmaceutical formulations. This includes oral solid doses, injectable solutions, ophthalmic preparations, liquid medications, topical applications, softgels, inhalants, and transdermal patches, all catering to a broad spectrum of medical needs. Within the Specialty division, the company concentrates on the advancement, marketing, sales, and distribution of proprietary branded pharmaceuticals. Key therapeutic areas for this segment include neurological conditions, endocrine disorders, and parasitic ailments, among others. Notable offerings include Emverm, a chewable tablet prescribed for single or mixed parasitic infections such as pinworm and various hookworms; Rytary, designed for the management of Parkinson's disease; and Unithroid, used in treating hypothyroidism. The AvKARE segment primarily serves governmental entities, particularly the Department of Defense and the Department of Veterans Affairs, supplying them with pharmaceuticals, medical and surgical supplies, and related services. Additionally, this segment engages in the bulk distribution of bottled and unit-dose pharmaceuticals under its AvKARE and AvPAK brands, alongside medical and surgical items. It also manages the packaging and large-scale distribution of medications and nutritional supplements for its retail and institutional clientele. Products from Amneal reach consumers through a network comprising wholesale suppliers, third-party distributors, hospitals, large pharmacy chains, and independent drugstores. Its operational footprint extends across the United States, India, Ireland, and other international markets. Established in 2002, the company was initially incorporated as Atlas Holdings, Inc., before adopting the name Amneal Pharmaceuticals, Inc. in 2018. Its corporate headquarters are situated in Bridgewater, New Jersey.
Harga Saham
$19.39
Terakhir disinkronkan: 2026-10-19
Kapitalisasi Pasar
$6.19B
Perubahan (1 hari)
1.09%
Perubahan (1 tahun)
89.36%
Negara
US
Perdagangan Amneal Pharmaceuticals, Inc. (AMRX)
Kategori
Healthcare
Rasio P/E untuk Amneal Pharmaceuticals, Inc. (AMRX)
Rasio P/E per October 2026 TTM: 37.99
Menurut laporan keuangan dan harga saham terbaru dari Amneal Pharmaceuticals, Inc., rasio P/E saat ini (TTM) adalah 37.99. Pada akhir 2023, perusahaan memiliki rasio P/E sebesar -12.65.
Riwayat rasio P/E untuk Amneal Pharmaceuticals, Inc. dari 2014 hingga 2026
Rasio P/E di akhir setiap tahun
| Tahun | Rasio P/E | Mengubah |
|---|---|---|
| 2026 (TTM) | 37.99 | -281.42% |
| 2024 | -20.94 | 65.56% |
| 2023 | -12.65 | 447.22% |
| 2022 | -2.31 | -103.44% |
| 2021 | 67.14 | 796.23% |
| 2020 | 7.49 | -810.26% |
| 2019 | -1.05 | -89.60% |
| 2018 | -10.14 | -188.93% |
| 2017 | 11.41 | -5.54% |
| 2016 | 12.08 | -74.68% |
| 2015 | 47.69 | 40.93% |
| 2014 | 33.84 | 0.00% |
Rasio P/E untuk perusahaan serupa atau pesaing
| Perusahaan | Rasio P/E | Perbedaan Rasio P/E | Negara |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 34.96 | -7.98% |
IN
|
Bagaimana cara membaca P/E ratio?
Rasio Harga/Laba (P/E) mengukur hubungan antara harga saham perusahaan dan laba per sahamnya.
P/E yang rendah namun positif menunjukkan perusahaan dengan laba tinggi dibandingkan valuasinya saat ini dan mungkin dianggap undervalued. P/E negatif tinggi (mendekati 0) menunjukkan perusahaan yang mengalami kerugian besar.
Perusahaan dengan P/E di atas 30 atau negatif umumnya dianggap sebagai "saham pertumbuhan", artinya investor mengharapkan pertumbuhan atau keuntungan di masa depan.
Perusahaan dengan P/E positif di bawah 10 dianggap sebagai "saham bernilai", artinya perusahaan sudah sangat menguntungkan dan pertumbuhannya kemungkinan tidak besar.